StockIQ.techRoivant Sciences Ltd. (ROIV) Stock Analysis
Free AI-powered analysis and research for Roivant Sciences Ltd. stock
Sector: Healthcare
ROIV snapshot
Data as of 3 Nov 2026 close. Updated daily.
Roivant Sciences Ltd. scores 63/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 73% of its 52-week range, up 85.1% over the past year. Latest reported figures show a profit margin of 0.0%, return on equity of -8.5% and revenue growth of -33.5%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bullish: +8
- Declining Revenue (-33.5%): -8
- Weak Profit Margin (0.0%): -8
- Low Debt (0.02 D/E): +8
- Strong Liquidity (16.72 Current Ratio): +8
- Negative ROE (-8.5%): -10
- High P/B (6.34): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+85.1% over 1 year): +10
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full ROIV report
Roivant Sciences Ltd. (ROIV) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze ROIV Now →📰 Latest Update
Roivant Sciences stock surges on positive uveitis trial data
Wed, October 21, 2026 at 1:09 PM UTC 3 min read
Roivant Sciences' stock experienced a significant surge following the release of positive trial data for its uveitis treatment. This promising development highlights the potential for successful commercialization, which could enhance the company's revenue prospects and attract investor interest. As clinical advancements often lead to increased stock valuations, this news is a crucial indicator of Roivant's growth potential in the biopharmaceutical sector.